Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Orange Book Blues

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The Food and Drug Administration's update of its Orange Book added the drugs approved last month, including VIVUS' (Nasdaq: VVUS  ) Qsymia and Onyx Pharmaceuticals' (Nasdaq: ONXX  ) Kyprolis.

But the entry for Amarin's (Nasdaq: AMRN  ) Vascepa isn't complete. As expected from a company SEC disclosure earlier, the entry includes patents, but doesn't include the regulatory exclusivity status of Vascepa.

The Orange Book's official actual title is Approved Drug Products with Therapeutic Equivalence Evaluations, but Selecting Drugs to Copycat (for Dummies!) might be a better title. It lists all the patents for branded drugs that keep generic versions off the market. Only drugs approved under the New Drug Application are included, so biologics like Abbott Labs' Humira and Amgen's Epogen aren't listed.

In case you're wondering, it's called the Orange Book because when there was a printed version, the cover was orange (back story here). But it's now available as a PDF -- with an orange cover page for posterity -- and a searchable database on the FDA's website.

Generic-drug makers can challenge patents in the Orange Book, and the FDA rewards the first company that's successful with a six-month generic exclusive before approving other generics.

In addition to the patents, the Orange Book lists other exclusivities that keep generics at bay. For example, new chemical entities, or NCEs, get five years of exclusivity. The term runs concurrent to the patents, but keeps generic-drug makers from challenging patents and applying to sell a generic immediately after approval.

It's the NCE status that's at question for Vascepa, a fish oil product that's more purified than GlaxoSmithKline's (NYSE: GSK  ) fish oil Lovaza. The FDA is still working through its decision about whether the drugs are different enough to classify Vascepa as new.

In the long run, it'll be Amarin's patents that protect Vascepa, but gaining NCE status is helpful in that it buys Amarin, or whoever buys the company, some breathing room. Unfortunately, it looks like investors will have to wait until at least next month's update to get a ruling.

The biggest binary event, the presidential election, is around the corner. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Read/Post Comments (3) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 20, 2012, at 11:21 AM, prginww wrote:

    Isn't VIVUS product a combination 2 other products?

    Then how did it get NCE?

  • Report this Comment On August 20, 2012, at 11:41 AM, prginww wrote:

    VIVUS' Qsymia didn't get NCE. It's listed as a NC (New combination), which gives the drug a 3 year exclusivity that run concurrently with patents.

  • Report this Comment On August 20, 2012, at 4:27 PM, prginww wrote:

    A PhD put to the test with all the meat and doritos of just another yahoo post.

    Although; Lovenox or leave it.

    "Today, there are many improved products on the market consisting of so-called low molecular weight heparins (LMWHs) that are produced by further refining and processing heparin to improve safety and efficacy... Compared to the above examples, the LMWHs are much more applicable to AMR101, and in my opinion offer support for granting NCE status to AMRN -"

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1989426, ~/Articles/ArticleHandler.aspx, 10/27/2016 9:12:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
AMRN $3.41 Down -0.04 -1.16%
Amarin CAPS Rating: ****
GSK $40.42 Up +0.08 +0.20%
GlaxoSmithKline CAPS Rating: ***
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **
VVUS $1.11 Down -0.01 -0.89%
VIVUS CAPS Rating: **